1. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Issue 5 (May 2021) Authors: Bottomley, Andrew; Coens, Corneel; Mierzynska, Justyna; Blank, Christian U; Mandalà, Mario; Long, Georgina V; Atkinson, Victoria G; Dalle, Stéphane; Haydon, Andrew M; Meshcheryakov, Andrey; Khattak, Adnan; Carlino, Matteo S; Sandhu, Shahneen; Puig, Susana; Ascierto, Paolo A; Larkin, James; Loriga... Journal: Lancet oncology Issue: Volume 22:Issue 5(2021) Page Start: 655 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. Issue 2 (24th December 2020) Authors: Ferrucci, Pier Francesco; Di Giacomo, Anna Maria; Del Vecchio, Michele; Atkinson, Victoria; Schmidt, Henrik; Schachter, Jacob; Queirolo, Paola; Long, Georgina V; Stephens, Rosalie; Svane, Inge Marie; Lotem, Michal; Abu-Amna, Mahmoud; Gasal, Eduard; Ghori, Razi; Diede, Scott J; Croydon, Elizabeth ... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Multidisciplinary management of metastatic melanoma to the inter‐atrial septum. Issue 3 (21st May 2017) Authors: Beliaev, Andrei M.; Ruygrok, Peter N.; Stephens, Rosalie; Haydock, David A. Journal: ANZ journal of surgery Issue: Volume 89:Issue 3(2019) Page Start: 258 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗